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Telomerase as a marker of tumour development – analysis of telomerase
expression and activity
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Danuta Januszkiewicz1, 3
I n t r o d u c t i o n. Reactivation of telomerase is believed to be an important factor of both immortalization and carcinogene-
sis. Despite criticisms of the etiopathological significance of telomerase in carcinogenesis, an evaluation of its expression and
activity may be considered to be a potentially useful diagnostic marker.
M a t e r i a l  a n d  m e t h o d s.  Telomerase expression has been studied by RT-PCR using specific primers for telomerase re-
verse trancriptase. Telomerase repeat amplification protocol-TRAP was used for the analysis of telomerase activity.
Re s u l t s.  In a preliminary study a high expression of telomerase in gastric and colon cancer, acute lymphoblastic and myelo-
blastic leukaemia, as well as in myeloid line K562 has been found. Lymphocytes stimulated by PHA have also revealed high
telomerase expression. Low telomerase expression has been found only in some cases of non-cancerous mucosa from corre-
sponding patients with gastric and colorectal cancer and peripheral blood lymphocytes. Telomerase activity in 10 000 cells has
been observed in all studied samples. 300-cells lysate of all cancer cells, as well as PHA stimulated lymphocytes showed telo-
merase activity, which is in contrary to normal cells.
C o n c l u s i o n s.  From these results one may conclude that all cancer cells tested have higher telomerase expression, as com-
pared to normal cells. Taking into account the clear-cut relationship between telomerase activity and cell number, it may be
postulated that either quantitative or semiquantitative evaluation of telomerase activity and expression should allow to distin-
guish cancer from normal tissue.
Telomeraza jako marker procesu nowotworowego – analiza ekspresji i aktywnoÊci
W s t ´ p. Przyjmuje si´, ˝e indukcja aktywnoÊci telomerazy odgrywa wa˝nà rol´ w immortalizacji komórek i w procesie nowo-
tworzenia. Pomimo szeregu zastrze˝eƒ co do znaczenia telomerazy w karcinogenezie, ocena jej ekspresji i aktywnoÊci mo˝e byç
przydatnym markerem procesu nowotworzenia.
M a t e r i a ∏  i m e t o d y.  Ekspresj´ telomerazy oceniano technikà RT-PCR, pos∏ugujàc si´ starterami swoistymi dla
genu odwrotnej transkryptazy. AktywnoÊç telomerazy analizowano reakcjà TRAP (telomerase repeat amplification
protocol).
W y n i k i. We wst´pnych badaniach stwierdzono wysokà ekspresj´ telomerazy w komórkach raka ˝o∏àdka i jelita grubego, ko-
mórkach ostrej bia∏aczki limfoblastycznej i mieloblastycznej oraz w komórkach linii K562. Podobnie wysokà ekspresj´ telo-
merazy wykazano w limfocytach krwi obwodowej, stymulowanych PHA. Niskà ekspresj´ telomerazy stwierdzono w komórkach
zmienionej zapalnie b∏ony Êluzowej ˝o∏àdka i jelita grubego. Jedynie w cz´Êci przypadków prawid∏owej b∏ony Êluzowej ˝o∏àd-
ka i jelita grubego oraz niestymulowanych limfocytów krwi obwodowej zdrowych dawców uda∏o si´ wykazaç niskà ekspresj´
telomerazy. AktywnoÊç telomerazy wykazano we wszystkich badanych próbach przy izolatach z 10 000 komórek. Wszystkie ko-
mórki nowotworowe i stymulowane PHA limfocyty wykazywa∏y aktywnoÊç telomerazy w lizacie z 300 i nawet z 30 komórek.
W lizacie z 300 komórek prawid∏owych (b∏ony Êluzowej ˝o∏àdka i jelita grubego oraz limfocytach) nie stwierdzano aktywno-
Êci telomerazy.
Po d s u m o w a n i e. Na podstawie przeprowadzonych badaƒ mo˝na stwierdziç, ˝e badane nowotwory wykazujà wy˝szà eks-
presj´ telomerazy w porównaniu z tkankami i komórkami prawid∏owymi. Wykazana w pracy zale˝noÊç aktywnoÊci telomera-
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Introduction
Telomeres, the stretches of DNA cup chromosomes, po-
sses short repeated units of conservative sequence
TTAGGG [1, 2]. In human telomere lengths are estima-
ted to be 5–15 thousand base pair, and in mice about 30
thousand.
Telomeres prevent chromosomes from degradation
and incorrect recombination. Cells lacking telomeres
show chromosome aberration [3]. A number of aberrant
chromosomes can be formed, including ring chromosome
due to end fusion, dicentric and multicentric chromoso-
mes. In somatic cells during subsequent division telome-
res lose 50–100 base pair. According to the Hayflick limit,
cells from various organisms undergo a limited number of
possible cell divisions [2]. However, in a recent study Cri-
stofalo and al. re-evaluated the relationship between do-
nor age and replicative livespan of human cells in culture
[4]. They found that the replicative livespan of fibroblast
in vitro culture does not correlate with the donor age.
Therefore the replicative livespan of normal cells in cultu-
re can’t be used as a model of human cell ageing. In germ
cells and in a majority of tumour cells telomeres do not
shorten owing to telomerase activity synthesising 5' end of
DNA chain, which is not being replicated.
Telomerase is a rybonucleoprotein complex consi-
sting of reverse transcriptase, proteins, and RNA tem-
plate for telomeric DNA synthesis [5, 6]. Each of the telo-
merase elements is encoded on a separate chromosome,
i.e. 5, 14 and 3 respectively. It is assumed that a cell which
has loost control on proliferation telomerase activity is, in
fact, induced. Origibally it had been assumed that telome-
rase is connected with tumour development. More than
80% of tumours possess telomerase activity. Experiments
with suppression of tumour development in vivo and in vi-
tro by switching telomerase activity suggested that telome-
rase itself may be an ideal target for anti-cancer therapy
[7, 8, 9]. Further studies have shown that some tumour
cells lack telomerase activity. Moreover, a number of tu-
mour cells have even shorter telomeres as compared to
normal cells. It was even postulated that short telome-
res accompanying crisis of cell division may be considered
a kind of promoters of tumour development [3].
The aim of this work was to analyse the telomerase
expression and activity in selected neoplasms and in my-
eloblasts cell line K562.
Our experiments have been designed in order to
evaluate the usefulness of telomerase activity and expres-
sion as tumour markers. The study was also performed on
inflammatory altered mucosa; PHA stimulated peripheral
blood lymphocytes, samples of normal tissues and lym-
phocytes.
Material and methods
Telomerase expression and activity have been assessed in the
following cells and tissue: acute lymphoblastic leukae-
mia (ALL) (n=10), acute non-lymphoblastic leukaemia
(ANLL-M1) (n=5), myeloblastic cell line K562, gastric cancer
(n=7), colon cancer (n=13), normal and inflammatory altered
mucosa from the stomach and the colon of corresponding pa-
tients, and normal and PHA stimulated peripheral blood lym-
phocytes from healthy individuals (n=14). Solid tissue was cut
with scissors, minced through a steel screen and passed through
nylon mesh. The obtained single-cell suspension was washed
twice with PBS, counted, and suspended to final concentra-
tion of 2 million per ml.
Telomerase expression was evaluated by RT-PCR techni-
que using specific primers for human telomerase reverse trans-
criptase gene (HTERT) [5, 6, 10]. RNA has been isolated from
2 million of either normal or tumour cells. PCR products have
been analysed by agarose gel electrophoresis. As a control cDNA
sequence of GAPDH (human glyceraldehyde-3-phosphate dehy-
drogenase) has been amplified.
Telomerase activity has been analysed with TRAp-eze -Te-
lomerase Detection Kit Assay (Oncor) [11, 12]. PCR products in
polyacryloamide gel were stained with Sybr Green (Sigma) and
visualised by gel documentation system CCD (Kodak).
Results
High telomerase expression has been found in all
tumour cells including those from gastric and colon can-
cer, ALL and ANLL blasts, as well as K562. Representa-
tive results are presented in Fig. 1. Similarly high telome-
rase expression has been found in PHA stimulated peri-
pheral blood lymphocytes. Inflammatory altered gastric
and colon mucosa show only low telomerase expression
(Fig.1). Only in some cases of normal gastric and colon
mucosa and in non-stimulated lymphocytes from healthy
zy od liczby badanych komórek wskazuje na koniecznoÊç zastosowania iloÊciowej lub pó∏iloÊciowej oceny aktywnoÊci i eks-
presji telomerazy w celu odró˝nienia tkanki nowotworowej od prawid∏owej.
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Fig. 1. Telomerase expression 1–100 bp DNA ladder (Rapidozym),
2,5-inflammatory altered gastric mucosa,  3,6-gastric cancer cells,
4,7 – normal gastric mucosa. Bands 2–4 HTERT, 5–7 GAPDH
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individuals (4/14) low telomerase expression has been
detected. The majority of mucosa samples and normal
lymphocytes have not shown any telomerase expression.
In contrary to the expression, telomerase activity ap-
peared to be positive in all samples tested in cases where
the lysate was obtained from 10 000 cells. Using 300-cell
lysate resulted in revealing clear-cut differences between
normal and cancer cells (Fig. 2). All tumour cells and
PHA stimulated lymphocytes showed telomerase activity
as detected from 300 cells. Telomerase activity in 300-
-cell lysate of gastric and colon mucosa (Fig. 2) or of nor-
mal lymphocytes has not been detected (data not shown).
In dose-dependent experiments telomerase activity has
been found up to 30-cell lysate in gastric and colon cancer
(data not shown). The highest telomerase activity revealed
in leukaemia cell and K562 cells – activity has been detec-
ted in 30-cell lysate (Fig. 3) and even in 10-cell lysate
(data not shown).
Discussion
On the basis of performed experiments it can be
concluded that tumour cells have higher telomerase
expression as compared to normal cells and tissue. These
observations are similar with those reported in literature
[10, 13].
The usefulness of telomerase activity as a tumour
marker is controversial. Most of the authors assessing te-
lomerase activity in prostate, colon and gastric cancer
have attempted to show practical significance of telome-
rase activity as a marker which may discriminate normal
tissue from neoplastically altered samples [16, 17, 18]. In
our experiments we have shown that the difference betwe-
en the tumour and healthy tissue is not as obvious as so-
me authors postulate [19, 20, 21]. Our results have shown
that both normal and cancer cells appeared to have telo-
merase activity as tested on 10 000-cell lysate. Some au-
thors have suggested that telomerase activity is just a mar-
ker of cell proliferation, and thus not directly associated
with neoplastic transformation [8].
In our opinion telomerase activity is present, to
a different degree, in all normal human cells and is only
a marker of cell proliferation. Various types of tissue
may have different telomerase activity depending, proba-
bly, on their proliferation rate. This would explain all
the results concerning telomerase activity, which we ha-
ve obtained. Studies of rapidly proliferating cancer cells
reveal telomerase activity comparable to PHA stimulated
lymphocytes.
The most important result of our work is the obvio-
us dependency of telomerase activity on cell quantity.
These results have prompted us to suggest that quantita-
tive evaluation of telomerase expression and activity may
be useful marker to distinguish tumour tissue from heal-
thy tissue. Combined tests expression and telomerase ac-
tivity seems to be a marker of tumour development. The-
se two markers may be considered useful for the identifi-
cation of pre-cancer state, as well as for the diagnosis the
cancer recurrence. Basing upon the obtained results we
may postulate that telomerase is, indeed, a tumour mar-
ker, no matter whether or not it is directly involved in
cancerogenesis.
Conclusions
The results of our study concerning the relationship be-
tween telomerase activity and cell number strongly ar-
gue for a need of applying quantitative or semiquantitati-
ve methods of telomerase evaluation in the discrimination
between healthy tissue and tumour cells. Further studies
should aim at stating whether telomerase will become
a prognostic marker competitive to others presently used.
This should result in the practical use of telomerase in
cancer diagnostics.
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Fig. 2. Telomerase activity and cell number in a gastric cancer patient
1,12- PCR low ladder, 20bp (Sigma), 2,3,7,8 -gastric cancer,
4,5,6-inflammatory altered gastric mucosa, 9,10,11-normal gastric
mucosa
Fig. 3. Telomerase activity and cell number 1,15- PCR low ladder, 20bp
(Sigma), 2-7 -ALL, 8-13 -normal lymphocytes, 14 -negative control
480
References
1. D∏ugosz A, Ciechanowicz A. Telomeraza a nowotwory przewodu pokar-
mowego. Pol Merkuriusz Lek 1998; 5: 57–9.
2. Hayflick L. How and why we age. Exp Gerontol 1998; 33: 639–53.
3. Hande MP, Samper E, Lansdorp P, et al. Telomere length dynamics and
chromosomal instability in cells derived from telomerase null mice. J Cell
Biol 1999; 144: 589–601.
4 Cristofalo VJ, Allen RG, Pignolo RJ, et al. Relationship between donor
age and the replicative lifespan of human cells in culture: A reevalu-
ation. Proc Natl Acad Sci USA 1998; 95:10614–10619.
5. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit
hTERT: organization of the gene and characterization of the promoter.
Hum Mol Genet 1999; 8: 137–42.
6. Wick M, Zubov D, Hagen G. Genomic organization and promoter charac-
terization of the gene encoding the human telomerase reverse transcrip-
tase (hTERT). Gene 1999; 232: 97–106.
7. Engelhardt M, Albanell J, Drullinsky P et al. Relative contribution of
normal and neoplastic cells determines telomerase activity and telomere
length in primary cancers of the prostate, colon, and sarcoma. Clin Can-
cer Res 1997; 3: 1849–57.
8. Tahara E. Molecular mechanism of human stomach carcinogenesis impli-
cated in Helicobacter pylori infection. Exp Toxicol Pathol 1998; 50: 375–8.
9. Zhang W, Piatyszek MA, Kobayashi T, et al. Telomerase activity in human
acute myelogenous leukemia: inhibition of telomerase activity by differen-
tiation-inducing agents. Clin Cancer Res 1996; 2: 799–803.
10. Yasui W, Tahara H, Tahara E, et al. Expression of telomerase catalytic
component, telomerase reverse transcriptase, in human gastric carcino-
mas. Jpn J Cancer Res 1998; 89: 1099–103.
11. Dalbagni G, Han W, Zhang ZF, et al. Evaluation of the telomeric repeat
amplification protocol (TRAP) assay for telomerase as a diagnostic moda-
lity in recurrent bladder cancer. Clin Cancer Res 1997; 3: 1593–8.
12. Nagai N, Oshita T, Murakami J, et al. Semiquantitative analysis of telome-
rase activity in cervical cancer and precancerous lesions. Oncol Rep 1999;
6: 325–8.
13. Hiyama T, Yokozaki H, Kitadai Y, et al. Overexpression of human telome-
rase RNA is an early event in oesophageal carcinogenesis. Virchows Arch
1999; 434: 483–7.
14. Caldini A, Gelmini S, Rapi S, et al. DNA ploidy, S phase fraction and te-
lomerase activity in gastric cancer. Eur J Histochem 1997; 41: 123–4.
15. Katayama S, Shiota G, Oshimura M, et al. Clinical usefulness of telo-
merase activity and telomere length in the preoperative diagnosis of ga-
stric and colorectal cancer. J Cancer Res Clin Oncol 1999; 125: 405–10.
16. Engelhardt M, Drullinsky P, Guillem J, et al. Telomerase and telomere
length in the development and progression of premalignant lesions to
colorectal cancer. Clin Cancer Res 1997; 3: 1931–41.
17. Fang DC, Young J, Luo YH, et al. Detection of telomerase activity in
biopsy samples of colorectal cancer. J Gastroenterol Hepatol 1999; 14:
328–32.
18. Sakurai S, Fukayama M, Kaizaki Y, et al. Telomerase activity in gastroin-
testinal stromal tumors. Cancer 1998; 83: 2060–6.
19. Tahara H, Kuniyasu H, Yokozaki H, et al. Telomerase activity in prene-
oplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res
1995; 1: 1245–51.
20. Tahara H, Yasui W, Tahara E, et al. Immuno-histochemical detection of
human telomerase catalytic component, hTERT, in human colorectal tu-
mor and non-tumor tissue sections. Oncogene 1999; 18: 1561–7.
20. Uchida N, Otsuka T, Arima F, et al. Correlation of telomerase activity with
development and progression of adult T-cell leukemia. Leuk Res 1999; 23:
311–6.
Paper received: 21 June 2000
Accepted: 12 August 2000
